This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Jul 2011

Mylan & Gilead Sign Agreement for HIV/AIDS Products

The expanded agreement allows for the sale of Viread, Truvada and other TDF-based combinations in 16 additional countries and for the production and sale of Viread as a treatment for chronic hepatitis B in an expanded territory.

Mylan's Matrix Laboratories Ltd. has signed an expanded licensing agreement with Gilead Sciences for the rights to produce and market generic versions of three Gilead HIV/AIDS therapies.


These products, currently in late-stage development, include: Elvitegravir, an investigational integrase inhibitor, Cobicistat, an investigational antiretroviral (ARV) boosting agent, and the "Quad," a once-daily, single-tablet combination of four separate Gilead medicines.


Mylan President Heather Bresch said: "Every patient living with HIV/AIDS has a right to treatment. Matrix has made a significant contribution to dramatically lowering the cost of HIV/AIDS medicines, and we are now focused on expanding access to high-quality treatment to more people who need it. We ar

Related News